Today: 22 March 2026
Subscribe
Browse Category

NASDAQ:CRNC 20 November 2025

Cerence (CRNC) Stock Soars After Q4 2025 Earnings Beat and Bold FY26 AI Guidance – November 20, 2025

Cerence (CRNC) Stock Soars After Q4 2025 Earnings Beat and Bold FY26 AI Guidance – November 20, 2025

Cerence Inc. shares jumped 38% to $10.95 in early trading Thursday after reporting Q4 revenue of $60.6 million, beating estimates and guidance. The company posted a Q4 net loss of about $13.4 million, improved from last year, and Q4 adjusted EBITDA of $8.3 million. Full-year free cash flow reached $46.8 million, nearly triple the prior year. Cerence technology was used in about 52% of global auto production over the past year.
20 November 2025
··

Stock Market Today

  • CRISPR Therapeutics Stock Dips Amid Biotech Risks Despite Strong DCF Upside
    March 22, 2026, 2:39 AM EDT. CRISPR Therapeutics (CRSP) shares have fallen 14% year to date, contrasting with a 12.2% gain over the past year. The stock trades around $46.24, reflecting a 75.6% discount to its intrinsic value based on a Discounted Cash Flow (DCF) model projecting positive free cash flow by 2030. Despite short-term declines driven by biotech sector volatility and regulatory concerns, long-term growth potential linked to its gene-editing pipeline keeps investor interest. The company shows a $345.4 million free cash flow loss currently, moving to forecasted positive cash generation. Valuation metrics like price-to-book provide additional context amid earnings volatility. Market watchers may consider CRISPR's current weakness an opportunity, though risks remain given sector dynamics and cash flow uncertainty.
Go toTop